Last updated on January 2019

A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment


Brief description of study

This is a two-part study of NUC-3373 administered every 2 weeks as an intravenous infusion, in separate combinations with leucovorin, oxaliplatin, oxaliplatin + bevacizumab, oxaliplatin + panitumumab, irinotecan, and irinotecan + cetuximab. The primary objective is to identify a recommended dose for NUC-3373 when combined with these agents.

Clinical Study Identifier: NCT03428958

Find a site near you

Start Over